Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach.

Kannan A. et al, (2025), Blood rev

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Perrot A. et al, (2025), Eur j haematol

Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper.

Pinney J. et al, (2025), Br j haematol

Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?

Vijjhalwar R. et al, (2025), Indian journal of hematology and blood transfusion

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Ramasamy K. et al, (2024), Clin lymphoma myeloma leuk

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service.

Popat R. et al, (2024), Ejhaem, 5, 1133 - 1143

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Kaiser M. et al, (2024), Br j haematol

Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil

Hungria V. et al, (2024), Cancers, 16

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Lee HC. et al, (2024), Eur j haematol

Challenges in designing and running smouldering myeloma interventional clinical trials.

Lecat C. et al, (2024), Ejhaem, 5, 418 - 420

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.

Ramasamy K. et al, (2024), Haematologica

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

Hughes D. et al, (2024), Br j haematol

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Agarwal G. et al, (2024), Haematologica

INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.

Leleu X. et al, (2024), Future oncol

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.

Lehne M. et al, (2023), Eur j haematol

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Twumasi C. et al, (2023), Eur j haematol

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Mitchell JL. et al, (2023), Platelets, 34

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.

Ludwig H. et al, (2023), Clin lymphoma myeloma leuk

Patient-reported symptoms and diagnostic journey in Multiple Myeloma.

Vijjhalwar R. et al, (2023), Front oncol, 13

Patient-reported symptoms and diagnostic journey in multiple myeloma

Vijjhalwar R. et al, (2023), British journal of haematology, 201, 71 - 71

Include forthcoming?